Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon

View original at finance.yahoo.com
Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoiners might be loving this store of value performance

    80% confidence

  • Rad AI's technology helps transform data chaos into actionable insights and high-performing content with measurable ROI

    80% confidence

  • Bitcoin dropped 48% from record highs to $65,000 in just four months, questioning its store of value narrative

    80% confidence

  • Paladin's ESS uses non-lithium, solid-state graphene battery technology designed for durability, safety, and long service life

    80% confidence

  • Elf Labs valuation growth exceeded 1,600% in under two years

    80% confidence

  • Atari Hotel Phoenix targets 15% preferred return and projected 5.8x multiple for investors

    80% confidence

  • Trillion-dollar stocks like Nvidia and Amazon experienced similar drawdowns and should never have a place in wealth portfolio if same standard applied to Bitcoin

    80% confidence

  • Bitcoin network functions as a global ledger for value transfer

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com